Magdalena Gorska
Concepts (362)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 24 | 2026 | 1795 | 2.770 |
Why?
| | Th2 Cells | 9 | 2024 | 175 | 2.140 |
Why?
| | Estradiol | 6 | 2016 | 507 | 2.120 |
Why?
| | Osteosarcoma | 5 | 2016 | 77 | 1.800 |
Why?
| | Hypersensitivity | 3 | 2026 | 254 | 1.610 |
Why?
| | Vehicle Emissions | 3 | 2020 | 61 | 1.530 |
Why?
| | Killer Cells, Natural | 5 | 2026 | 480 | 1.430 |
Why?
| | Environmental Exposure | 2 | 2026 | 577 | 1.380 |
Why?
| | Adaptor Proteins, Signal Transducing | 8 | 2012 | 426 | 1.330 |
Why?
| | Nitric Oxide Synthase Type I | 3 | 2015 | 30 | 1.330 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2026 | 651 | 1.260 |
Why?
| | Maternal Exposure | 4 | 2020 | 188 | 1.210 |
Why?
| | Air Pollutants | 3 | 2026 | 433 | 1.150 |
Why?
| | Lymphocytes | 7 | 2026 | 379 | 0.960 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 4 | 2021 | 16 | 0.930 |
Why?
| | Allergens | 8 | 2026 | 390 | 0.830 |
Why?
| | Bone Neoplasms | 3 | 2016 | 256 | 0.820 |
Why?
| | Interleukin-17 | 4 | 2020 | 120 | 0.770 |
Why?
| | Lactams, Macrocyclic | 2 | 2013 | 51 | 0.740 |
Why?
| | Benzoquinones | 2 | 2013 | 47 | 0.740 |
Why?
| | Signal Transduction | 15 | 2026 | 5202 | 0.650 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2207 | 0.640 |
Why?
| | Mice | 27 | 2026 | 18338 | 0.640 |
Why?
| | Granzymes | 1 | 2020 | 49 | 0.630 |
Why?
| | Mutation, Missense | 2 | 2012 | 338 | 0.630 |
Why?
| | Oxidative Stress | 6 | 2016 | 1350 | 0.580 |
Why?
| | Animals | 33 | 2026 | 38141 | 0.550 |
Why?
| | Chaperonin 60 | 2 | 2016 | 13 | 0.520 |
Why?
| | Protein Tyrosine Phosphatases | 5 | 2016 | 167 | 0.520 |
Why?
| | Bronchial Hyperreactivity | 5 | 2015 | 104 | 0.520 |
Why?
| | Heat-Shock Proteins | 2 | 2016 | 134 | 0.500 |
Why?
| | Apoptosis | 6 | 2016 | 2411 | 0.480 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2016 | 139 | 0.480 |
Why?
| | Estrogen Antagonists | 1 | 2016 | 37 | 0.470 |
Why?
| | Estrogen Receptor beta | 1 | 2016 | 40 | 0.470 |
Why?
| | DNA Breaks | 1 | 2015 | 3 | 0.460 |
Why?
| | Interleukin-1beta | 1 | 2017 | 390 | 0.450 |
Why?
| | Bacterial Outer Membrane Proteins | 4 | 2016 | 61 | 0.450 |
Why?
| | Mitochondrial Proteins | 2 | 2016 | 262 | 0.440 |
Why?
| | Intracellular Signaling Peptides and Proteins | 6 | 2021 | 456 | 0.430 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 192 | 0.430 |
Why?
| | Cytokines | 8 | 2026 | 2054 | 0.430 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2011 | 673 | 0.420 |
Why?
| | Neuroblastoma | 1 | 2016 | 174 | 0.420 |
Why?
| | Virus Diseases | 1 | 2017 | 218 | 0.420 |
Why?
| | Protein Processing, Post-Translational | 5 | 2016 | 468 | 0.410 |
Why?
| | Cell Line, Tumor | 8 | 2016 | 3537 | 0.410 |
Why?
| | Leukocyte Common Antigens | 4 | 2015 | 87 | 0.400 |
Why?
| | Neurodegenerative Diseases | 1 | 2016 | 150 | 0.390 |
Why?
| | Cell Survival | 8 | 2016 | 1094 | 0.390 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 441 | 0.380 |
Why?
| | Immunity, Innate | 5 | 2024 | 846 | 0.370 |
Why?
| | Hippocampus | 2 | 2015 | 969 | 0.370 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2021 | 1138 | 0.370 |
Why?
| | Lymphopenia | 1 | 2012 | 64 | 0.370 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2012 | 46 | 0.360 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2011 | 6 | 0.360 |
Why?
| | Humans | 50 | 2026 | 145491 | 0.350 |
Why?
| | Cell Proliferation | 9 | 2021 | 2499 | 0.340 |
Why?
| | Lymphocyte Activation | 6 | 2021 | 1134 | 0.340 |
Why?
| | Inflammation | 2 | 2017 | 2883 | 0.340 |
Why?
| | Disease Models, Animal | 8 | 2022 | 4559 | 0.330 |
Why?
| | Gene Expression Regulation | 5 | 2026 | 2594 | 0.320 |
Why?
| | Neoplasms | 2 | 2016 | 2897 | 0.310 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2016 | 191 | 0.310 |
Why?
| | rab GTP-Binding Proteins | 2 | 2010 | 76 | 0.300 |
Why?
| | Interleukin-13 | 3 | 2020 | 146 | 0.300 |
Why?
| | Immunological Synapses | 1 | 2009 | 16 | 0.300 |
Why?
| | Membrane Proteins | 3 | 2025 | 1164 | 0.290 |
Why?
| | Epigenesis, Genetic | 2 | 2026 | 672 | 0.290 |
Why?
| | Cell Differentiation | 4 | 2020 | 2045 | 0.290 |
Why?
| | Ovalbumin | 3 | 2022 | 194 | 0.290 |
Why?
| | Hydrogen Peroxide | 4 | 2015 | 338 | 0.280 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 5 | 2021 | 135 | 0.270 |
Why?
| | Pregnancy | 5 | 2026 | 7197 | 0.270 |
Why?
| | Mice, Knockout | 7 | 2025 | 3125 | 0.250 |
Why?
| | Transcription, Genetic | 3 | 2026 | 1468 | 0.250 |
Why?
| | Interleukin-5 | 2 | 2008 | 39 | 0.250 |
Why?
| | Capillary Permeability | 1 | 2007 | 132 | 0.250 |
Why?
| | Mice, Inbred BALB C | 5 | 2022 | 1261 | 0.240 |
Why?
| | Dynamin II | 1 | 2006 | 3 | 0.240 |
Why?
| | Aurintricarboxylic Acid | 2 | 2016 | 4 | 0.240 |
Why?
| | Bronchoalveolar Lavage | 2 | 2018 | 88 | 0.240 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 2 | 2015 | 9 | 0.230 |
Why?
| | Neutrophils | 2 | 2025 | 1124 | 0.230 |
Why?
| | Respiratory Tract Diseases | 1 | 2007 | 176 | 0.230 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2026 | 66 | 0.230 |
Why?
| | Immunoglobulin E | 3 | 2018 | 315 | 0.220 |
Why?
| | Cytosol | 1 | 2026 | 214 | 0.220 |
Why?
| | T-Lymphocytes | 4 | 2009 | 1996 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 2030 | 0.210 |
Why?
| | Th17 Cells | 2 | 2016 | 100 | 0.210 |
Why?
| | Transforming Growth Factor beta | 4 | 2012 | 475 | 0.210 |
Why?
| | Cell Death | 2 | 2016 | 383 | 0.210 |
Why?
| | Disease Susceptibility | 2 | 2017 | 343 | 0.200 |
Why?
| | Jurkat Cells | 5 | 2015 | 115 | 0.200 |
Why?
| | Cells, Cultured | 7 | 2020 | 4127 | 0.200 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 1212 | 0.200 |
Why?
| | Biomarkers | 4 | 2026 | 4283 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2022 | 636 | 0.200 |
Why?
| | NF-kappa B | 1 | 2007 | 660 | 0.200 |
Why?
| | Mast Cells | 1 | 2024 | 148 | 0.190 |
Why?
| | Mice, Inbred C57BL | 7 | 2021 | 5989 | 0.190 |
Why?
| | Air Pollution | 1 | 2026 | 321 | 0.190 |
Why?
| | MAP Kinase Signaling System | 4 | 2021 | 306 | 0.190 |
Why?
| | Catalytic Domain | 4 | 2016 | 235 | 0.190 |
Why?
| | Molecular Docking Simulation | 4 | 2016 | 123 | 0.180 |
Why?
| | Immune System | 1 | 2003 | 178 | 0.170 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2012 | 70 | 0.170 |
Why?
| | Pleurotus | 1 | 2021 | 1 | 0.170 |
Why?
| | Female | 18 | 2026 | 78763 | 0.170 |
Why?
| | src-Family Kinases | 4 | 2012 | 92 | 0.170 |
Why?
| | Nitric Oxide | 2 | 2016 | 894 | 0.160 |
Why?
| | Phosphorylation | 5 | 2021 | 1707 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2016 | 536 | 0.160 |
Why?
| | Interleukin-33 | 2 | 2017 | 45 | 0.160 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2020 | 11 | 0.160 |
Why?
| | Receptors, Prostaglandin | 1 | 2020 | 21 | 0.160 |
Why?
| | Enzyme Activation | 6 | 2012 | 762 | 0.150 |
Why?
| | Protein Transport | 2 | 2013 | 438 | 0.150 |
Why?
| | Carrier Proteins | 1 | 2004 | 733 | 0.150 |
Why?
| | Protein Binding | 7 | 2016 | 2250 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 3 | 2010 | 171 | 0.150 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 2 | 2016 | 44 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2021 | 368 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2016 | 44 | 0.140 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 206 | 0.140 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 257 | 0.140 |
Why?
| | DNA | 1 | 2025 | 1451 | 0.140 |
Why?
| | Interleukin-9 | 1 | 2017 | 12 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 1 | 2026 | 2355 | 0.130 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 22 | 0.130 |
Why?
| | Immunization | 2 | 2018 | 375 | 0.130 |
Why?
| | Adoptive Transfer | 3 | 2021 | 199 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1509 | 0.130 |
Why?
| | Enzyme Inhibitors | 3 | 2015 | 821 | 0.130 |
Why?
| | Virulence Factors | 2 | 2016 | 177 | 0.130 |
Why?
| | Lymphocyte Subsets | 1 | 2017 | 79 | 0.130 |
Why?
| | Endocytosis | 2 | 2009 | 168 | 0.120 |
Why?
| | Yersinia | 1 | 2016 | 2 | 0.120 |
Why?
| | Enzyme Induction | 2 | 2014 | 88 | 0.120 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2016 | 17 | 0.120 |
Why?
| | Toluidines | 1 | 2016 | 10 | 0.120 |
Why?
| | Rosaniline Dyes | 1 | 2016 | 15 | 0.120 |
Why?
| | Benzenesulfonates | 1 | 2016 | 22 | 0.120 |
Why?
| | Acetylation | 2 | 2016 | 250 | 0.120 |
Why?
| | Drug Resistance | 1 | 2017 | 146 | 0.120 |
Why?
| | Caffeic Acids | 1 | 2016 | 2 | 0.120 |
Why?
| | Yersinia enterocolitica | 1 | 2016 | 7 | 0.120 |
Why?
| | Succinates | 1 | 2016 | 24 | 0.120 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2016 | 74 | 0.120 |
Why?
| | Microtubule Proteins | 2 | 2007 | 13 | 0.120 |
Why?
| | Tubulin Modulators | 1 | 2015 | 11 | 0.120 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 98 | 0.110 |
Why?
| | Ferrous Compounds | 1 | 2015 | 26 | 0.110 |
Why?
| | Tumor Suppressor p53-Binding Protein 1 | 1 | 2015 | 14 | 0.110 |
Why?
| | Cell Culture Techniques | 2 | 2016 | 373 | 0.110 |
Why?
| | Peroxides | 1 | 2015 | 19 | 0.110 |
Why?
| | Reactive Nitrogen Species | 1 | 2015 | 16 | 0.110 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2015 | 23 | 0.110 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 138 | 0.110 |
Why?
| | Calcifediol | 1 | 2015 | 31 | 0.110 |
Why?
| | Drug Synergism | 1 | 2016 | 353 | 0.110 |
Why?
| | Active Transport, Cell Nucleus | 2 | 2012 | 120 | 0.110 |
Why?
| | Antibodies, Blocking | 1 | 2015 | 38 | 0.110 |
Why?
| | Cytokinesis | 1 | 2015 | 50 | 0.110 |
Why?
| | Lipid Peroxidation | 1 | 2015 | 163 | 0.110 |
Why?
| | Estrogen Receptor alpha | 1 | 2016 | 151 | 0.110 |
Why?
| | Mucus | 2 | 2017 | 75 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 2 | 2012 | 280 | 0.100 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2016 | 214 | 0.100 |
Why?
| | Doxorubicin | 1 | 2016 | 398 | 0.100 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 265 | 0.100 |
Why?
| | Cellular Senescence | 1 | 2016 | 225 | 0.100 |
Why?
| | Growth Inhibitors | 2 | 2012 | 39 | 0.100 |
Why?
| | Histones | 2 | 2016 | 663 | 0.100 |
Why?
| | Interleukin-4 | 2 | 2014 | 208 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 180 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2009 | 384 | 0.100 |
Why?
| | Alternaria | 2 | 2025 | 9 | 0.100 |
Why?
| | Lung | 2 | 2022 | 4103 | 0.100 |
Why?
| | Molecular Dynamics Simulation | 4 | 2016 | 266 | 0.100 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 691 | 0.100 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2013 | 60 | 0.100 |
Why?
| | Interleukins | 1 | 2015 | 249 | 0.100 |
Why?
| | Myristic Acids | 1 | 2012 | 7 | 0.100 |
Why?
| | Swine | 1 | 2016 | 833 | 0.100 |
Why?
| | Myristic Acid | 1 | 2012 | 8 | 0.100 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2012 | 11 | 0.100 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Carcinogenesis | 1 | 2015 | 227 | 0.090 |
Why?
| | Retinal Dystrophies | 1 | 2012 | 4 | 0.090 |
Why?
| | Pre-Eclampsia | 1 | 2015 | 206 | 0.090 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2012 | 22 | 0.090 |
Why?
| | Novobiocin | 1 | 2012 | 4 | 0.090 |
Why?
| | DNA Damage | 1 | 2015 | 434 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2012 | 45 | 0.090 |
Why?
| | Macrolides | 1 | 2012 | 69 | 0.090 |
Why?
| | Child | 2 | 2026 | 22680 | 0.090 |
Why?
| | Pyrrolidinones | 1 | 2011 | 29 | 0.090 |
Why?
| | Models, Biological | 2 | 2012 | 1815 | 0.090 |
Why?
| | Endosomes | 2 | 2010 | 140 | 0.090 |
Why?
| | Tissue Engineering | 1 | 2016 | 441 | 0.090 |
Why?
| | Culture Media | 1 | 2011 | 163 | 0.080 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2012 | 122 | 0.080 |
Why?
| | Triazoles | 1 | 2012 | 184 | 0.080 |
Why?
| | Age of Onset | 1 | 2012 | 554 | 0.080 |
Why?
| | Enzyme Stability | 1 | 2010 | 73 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 1439 | 0.080 |
Why?
| | Actins | 2 | 2009 | 421 | 0.080 |
Why?
| | Biosensing Techniques | 1 | 2011 | 140 | 0.080 |
Why?
| | Dynamins | 1 | 2009 | 36 | 0.080 |
Why?
| | Eosinophils | 2 | 2012 | 316 | 0.070 |
Why?
| | Ambrosia | 1 | 2009 | 6 | 0.070 |
Why?
| | Aspergillus | 1 | 2009 | 18 | 0.070 |
Why?
| | Th1 Cells | 1 | 2010 | 139 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1162 | 0.070 |
Why?
| | Pyroglyphidae | 1 | 2009 | 18 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 440 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 1769 | 0.070 |
Why?
| | Myosins | 1 | 2009 | 133 | 0.070 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 632 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 313 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2016 | 1112 | 0.070 |
Why?
| | Arthritis, Experimental | 1 | 2010 | 141 | 0.070 |
Why?
| | Antigen Presentation | 1 | 2009 | 207 | 0.070 |
Why?
| | Indoles | 1 | 2012 | 508 | 0.070 |
Why?
| | eIF-2 Kinase | 1 | 2008 | 29 | 0.070 |
Why?
| | Multiprotein Complexes | 1 | 2009 | 172 | 0.070 |
Why?
| | Cytoskeleton | 1 | 2009 | 198 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-fyn | 1 | 2007 | 10 | 0.070 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 9 | 0.070 |
Why?
| | GATA3 Transcription Factor | 2 | 2020 | 22 | 0.070 |
Why?
| | Transfection | 2 | 2007 | 925 | 0.060 |
Why?
| | Umbilical Veins | 1 | 2007 | 56 | 0.060 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2007 | 113 | 0.060 |
Why?
| | Eye Proteins | 1 | 2007 | 85 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2010 | 505 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1367 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2008 | 287 | 0.060 |
Why?
| | Mitochondria | 1 | 2013 | 990 | 0.060 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2006 | 20 | 0.060 |
Why?
| | Feedback | 1 | 2007 | 181 | 0.060 |
Why?
| | Bronchi | 1 | 2008 | 263 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2006 | 130 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2026 | 1247 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 2004 | 535 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2008 | 339 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 174 | 0.060 |
Why?
| | Methylation | 1 | 2026 | 242 | 0.060 |
Why?
| | Tyrosine | 1 | 2006 | 219 | 0.060 |
Why?
| | Adult | 7 | 2021 | 40707 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 322 | 0.060 |
Why?
| | Down-Regulation | 2 | 2021 | 616 | 0.060 |
Why?
| | Neurons | 1 | 2014 | 1647 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2010 | 2189 | 0.050 |
Why?
| | Molecular Structure | 2 | 2016 | 498 | 0.050 |
Why?
| | Cell Line | 3 | 2016 | 2823 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2014 | 1156 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1049 | 0.050 |
Why?
| | src Homology Domains | 1 | 2004 | 35 | 0.050 |
Why?
| | Rats | 2 | 2010 | 5581 | 0.050 |
Why?
| | Nerve Tissue Proteins | 2 | 2009 | 590 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2664 | 0.050 |
Why?
| | Helminth Proteins | 1 | 2002 | 24 | 0.050 |
Why?
| | Middle Aged | 7 | 2021 | 36176 | 0.050 |
Why?
| | Antigen-Presenting Cells | 1 | 2003 | 159 | 0.050 |
Why?
| | Kinetics | 2 | 2015 | 1605 | 0.040 |
Why?
| | Fibroblasts | 1 | 2007 | 1023 | 0.040 |
Why?
| | Mutation | 1 | 2012 | 4093 | 0.040 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2945 | 0.040 |
Why?
| | DNA Methylation | 1 | 2026 | 667 | 0.040 |
Why?
| | Phytotherapy | 1 | 2021 | 74 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 951 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2021 | 77 | 0.040 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2002 | 207 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2020 | 161 | 0.040 |
Why?
| | NIH 3T3 Cells | 2 | 2009 | 147 | 0.030 |
Why?
| | Chemokines | 2 | 2009 | 218 | 0.030 |
Why?
| | Respiratory Hypersensitivity | 1 | 2017 | 65 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2003 | 878 | 0.030 |
Why?
| | Chaperonins | 1 | 2016 | 6 | 0.030 |
Why?
| | Serum Amyloid A Protein | 1 | 2016 | 32 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 580 | 0.030 |
Why?
| | RNA | 1 | 2003 | 929 | 0.030 |
Why?
| | Complement C3a | 1 | 2016 | 40 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 106 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 160 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 118 | 0.030 |
Why?
| | Young Adult | 2 | 2010 | 14192 | 0.030 |
Why?
| | Chlorogenic Acid | 1 | 2016 | 4 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1816 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 170 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2016 | 316 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 320 | 0.030 |
Why?
| | Breeding | 1 | 2016 | 63 | 0.030 |
Why?
| | Peracetic Acid | 1 | 2015 | 4 | 0.030 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 2015 | 10 | 0.030 |
Why?
| | Cell Extracts | 1 | 2015 | 21 | 0.030 |
Why?
| | Enzyme Assays | 1 | 2015 | 25 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2015 | 102 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2017 | 543 | 0.030 |
Why?
| | Yersinia pestis | 1 | 2015 | 45 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 147 | 0.030 |
Why?
| | Aged | 3 | 2010 | 26125 | 0.030 |
Why?
| | Phenotype | 1 | 2003 | 3157 | 0.030 |
Why?
| | Male | 6 | 2025 | 72817 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2015 | 81 | 0.030 |
Why?
| | Plague | 1 | 2015 | 60 | 0.030 |
Why?
| | Cysteine | 1 | 2016 | 208 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 133 | 0.030 |
Why?
| | Airway Remodeling | 1 | 2015 | 63 | 0.030 |
Why?
| | Virulence | 1 | 2015 | 282 | 0.030 |
Why?
| | Drug Interactions | 1 | 2015 | 404 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 297 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2014 | 227 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 850 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2016 | 855 | 0.020 |
Why?
| | Adolescent | 2 | 2010 | 22485 | 0.020 |
Why?
| | Carboxylic Acids | 1 | 2012 | 33 | 0.020 |
Why?
| | Binding Sites | 1 | 2016 | 1313 | 0.020 |
Why?
| | Dexamethasone | 1 | 2014 | 366 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2012 | 196 | 0.020 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2011 | 20 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 202 | 0.020 |
Why?
| | Stereoisomerism | 1 | 2011 | 103 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1080 | 0.020 |
Why?
| | Models, Molecular | 1 | 2016 | 1614 | 0.020 |
Why?
| | Clonal Anergy | 1 | 2010 | 54 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2014 | 531 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 116 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 364 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 304 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3619 | 0.020 |
Why?
| | GTP Phosphohydrolases | 1 | 2009 | 93 | 0.020 |
Why?
| | Placenta | 1 | 2015 | 784 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 839 | 0.020 |
Why?
| | Chemokine CCL11 | 1 | 2008 | 25 | 0.020 |
Why?
| | Autocrine Communication | 1 | 2008 | 38 | 0.020 |
Why?
| | Bacteria | 1 | 2015 | 897 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2008 | 178 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 153 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1855 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2862 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2008 | 321 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 51 | 0.020 |
Why?
| | Bronchial Provocation Tests | 1 | 2006 | 47 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2006 | 112 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1478 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2009 | 499 | 0.010 |
Why?
| | Blood Vessels | 1 | 2006 | 167 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 848 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 393 | 0.010 |
Why?
| | Receptors, Interleukin-5 | 1 | 2002 | 4 | 0.010 |
Why?
| | Receptors, Interleukin | 1 | 2002 | 43 | 0.010 |
Why?
| | DNA Primers | 1 | 2002 | 507 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 980 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1659 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2180 | 0.010 |
Why?
| | Prevalence | 1 | 2006 | 2855 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2137 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2910 | 0.010 |
Why?
|
|
Gorska's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|